Posttreatment Lyme Disease Syndrome

Research output: Contribution to journalArticle

Abstract

The prognosis following appropriate antibiotic treatment of early or late Lyme disease is favorable but can be complicated by persistent symptoms of unknown cause termed posttreatment Lyme disease syndrome (PTLDS), characterized by fatigue, musculoskeletal pain, and cognitive complaints that persist for 6months or longer after completion of antibiotic therapy. Risk factors include delayed diagnosis, increased severity of symptoms, and presence of neurologic symptoms at time of initial treatment. Two-tier serologic testing is neither sensitive nor specific for diagnosis of PTLDS because of variability in convalescent serologic responses after treatment of early Lyme disease. Optimal treatment of PTLDS awaits more precise understanding of the pathophysiologic mechanisms involved in this illness and future treatment trials.

Original languageEnglish (US)
Pages (from-to)309-323
Number of pages15
JournalInfectious Disease Clinics of North America
Volume29
Issue number2
DOIs
StatePublished - Jun 1 2015

Fingerprint

Lyme Disease
Therapeutics
Anti-Bacterial Agents
Musculoskeletal Pain
Delayed Diagnosis
Neurologic Manifestations
Fatigue

Keywords

  • Fatigue
  • Fibromyalgia
  • Musculoskeletal pain
  • Persistent symptoms
  • Posttreatment Lyme disease syndrome

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Cite this

Posttreatment Lyme Disease Syndrome. / Aucott, John.

In: Infectious Disease Clinics of North America, Vol. 29, No. 2, 01.06.2015, p. 309-323.

Research output: Contribution to journalArticle

@article{7baebdfa7a9a430b964095f39453341b,
title = "Posttreatment Lyme Disease Syndrome",
abstract = "The prognosis following appropriate antibiotic treatment of early or late Lyme disease is favorable but can be complicated by persistent symptoms of unknown cause termed posttreatment Lyme disease syndrome (PTLDS), characterized by fatigue, musculoskeletal pain, and cognitive complaints that persist for 6months or longer after completion of antibiotic therapy. Risk factors include delayed diagnosis, increased severity of symptoms, and presence of neurologic symptoms at time of initial treatment. Two-tier serologic testing is neither sensitive nor specific for diagnosis of PTLDS because of variability in convalescent serologic responses after treatment of early Lyme disease. Optimal treatment of PTLDS awaits more precise understanding of the pathophysiologic mechanisms involved in this illness and future treatment trials.",
keywords = "Fatigue, Fibromyalgia, Musculoskeletal pain, Persistent symptoms, Posttreatment Lyme disease syndrome",
author = "John Aucott",
year = "2015",
month = "6",
day = "1",
doi = "10.1016/j.idc.2015.02.012",
language = "English (US)",
volume = "29",
pages = "309--323",
journal = "Infectious Disease Clinics of North America",
issn = "0891-5520",
publisher = "W.B. Saunders Ltd",
number = "2",

}

TY - JOUR

T1 - Posttreatment Lyme Disease Syndrome

AU - Aucott, John

PY - 2015/6/1

Y1 - 2015/6/1

N2 - The prognosis following appropriate antibiotic treatment of early or late Lyme disease is favorable but can be complicated by persistent symptoms of unknown cause termed posttreatment Lyme disease syndrome (PTLDS), characterized by fatigue, musculoskeletal pain, and cognitive complaints that persist for 6months or longer after completion of antibiotic therapy. Risk factors include delayed diagnosis, increased severity of symptoms, and presence of neurologic symptoms at time of initial treatment. Two-tier serologic testing is neither sensitive nor specific for diagnosis of PTLDS because of variability in convalescent serologic responses after treatment of early Lyme disease. Optimal treatment of PTLDS awaits more precise understanding of the pathophysiologic mechanisms involved in this illness and future treatment trials.

AB - The prognosis following appropriate antibiotic treatment of early or late Lyme disease is favorable but can be complicated by persistent symptoms of unknown cause termed posttreatment Lyme disease syndrome (PTLDS), characterized by fatigue, musculoskeletal pain, and cognitive complaints that persist for 6months or longer after completion of antibiotic therapy. Risk factors include delayed diagnosis, increased severity of symptoms, and presence of neurologic symptoms at time of initial treatment. Two-tier serologic testing is neither sensitive nor specific for diagnosis of PTLDS because of variability in convalescent serologic responses after treatment of early Lyme disease. Optimal treatment of PTLDS awaits more precise understanding of the pathophysiologic mechanisms involved in this illness and future treatment trials.

KW - Fatigue

KW - Fibromyalgia

KW - Musculoskeletal pain

KW - Persistent symptoms

KW - Posttreatment Lyme disease syndrome

UR - http://www.scopus.com/inward/record.url?scp=84929622732&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84929622732&partnerID=8YFLogxK

U2 - 10.1016/j.idc.2015.02.012

DO - 10.1016/j.idc.2015.02.012

M3 - Article

VL - 29

SP - 309

EP - 323

JO - Infectious Disease Clinics of North America

JF - Infectious Disease Clinics of North America

SN - 0891-5520

IS - 2

ER -